/LYS.PA
LYS.PA Stock - Lysogene S.A.
Healthcare|BiotechnologyPAR
$0.28+0.00%
+$0.00 (+0.00%) • Jan 5
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.20
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.84
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.31
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for LYS.PA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.28 – $0.28
TARGET (TP)$0.32
STOP LOSS$0.26
RISK/REWARD1:2.1
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.91
52W High$0.82
52W Low$0.23
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|
| Revenue | $3.73M | $13.37M | $13.37M | $3.59M | N/A |
| Gross Profit | $1.84M | $10.75M | $10.89M | $3.59M | N/A |
| Gross Margin | 49.4% | 80.4% | 81.4% | 100.0% | N/A |
| Operating Income | $-13,291,000 | $-5,077,000 | $-5,083,000 | $-10,955,000 | $-17,216,000 |
| Net Income | $-13,671,000 | $-5,105,000 | $-3,481,000 | $-10,956,000 | $-17,795,000 |
| Net Margin | -366.4% | -38.2% | -26.0% | -305.2% | N/A |
| EPS | $-0.81 | $-0.32 | $-0.26 | $-0.87 | $-1.52 |
Company Overview
Lysogene S.A., a biopharmaceutical gene therapy company, focuses on the discovery and development of therapies for children with neurodegenerative lysosomal storage disorders. Its clinical programs include LYS-SAF302, which is in Phase II/III clinical trial for the treatment of mucopolysaccharidosis type IIIA; and LYS-GM101 that is in Phase I/II trial for the treatment of GM1 gangliosidosis. The company has a collaborative research collaboration with the Weizmann Institute of Science for developing a novel AAV gene therapy approach for neuronopathic gaucher disease, parkinson disease, and other diseases. Lysogene S.A. was incorporated in 2009 and is based in Neuilly-sur-Seine, France.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
LYS.PABeat Rate
0%
Last 0 quarters
Avg Surprise
+0%
EPS vs Estimate
Beats / Misses
0/0
Last 12 quarters
Latest EPS
$-0.10
Q4 2019
EPS Surprise History
Q2 17
No data
Q4 17
No data
Q2 18
No data
Q4 18
No data
Q2 19
No data
Q4 19
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2022 | Oct 14, 2022 | — | — | — | — |
Q3 2022 | Jul 21, 2022 | — | — | — | — |
Q2 2022 | Apr 28, 2022 | — | — | — | — |
Q4 2021 | Oct 8, 2021 | — | — | — | — |
Q2 2021 | Apr 29, 2021 | — | — | — | — |
Q4 2020 | Oct 23, 2020 | — | — | — | — |
Q3 2020 | Jul 24, 2020 | — | — | — | — |
Q2 2020 | Apr 22, 2020 | — | — | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.10 | — | — |
Q4 2019 | Nov 21, 2019 | — | — | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.16 | — | — |
Q2 2019 | Apr 11, 2019 | — | — | — | — |
Q4 2018 | Dec 31, 2018 | — | $-0.08 | — | — |
Q4 2018 | Oct 30, 2018 | — | — | — | — |
Q2 2018 | Jun 30, 2018 | — | $-0.22 | — | — |
Q1 2018 | Mar 26, 2018 | — | — | — | — |
Q4 2017 | Dec 31, 2017 | — | $-0.22 | — | — |
Q4 2017 | Oct 16, 2017 | — | — | — | — |
Q2 2017 | Jun 30, 2017 | — | $-0.38 | — | — |
Q2 2017 | Apr 21, 2017 | — | — | — | — |
Latest News
Loading news...
Frequently Asked Questions about LYS.PA
What is LYS.PA's current stock price?
Lysogene S.A. (LYS.PA) is currently trading at $0.28 per share. The stock has moved +0.00% today.
What is the analyst price target for LYS.PA?
No analyst price targets are currently available for this stock.
What sector is Lysogene S.A. in?
Lysogene S.A. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the PAR exchange.
What is LYS.PA's market cap?
Lysogene S.A. has a market capitalization of $0.00 billion, making it a small-cap company.
Does LYS.PA pay dividends?
No, Lysogene S.A. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALACT.PA
Acticor Biotech SAS
$0.25
Mkt Cap: $0.0B
ALCAR.PA
Carmat S.A.
$0.10
Mkt Cap: $0.0B
ALDEI.PA
Deinove S.A.
$0.03
Mkt Cap: $0.0B
ALHYG.PA
Hybrigenics S.A.
$0.01
Mkt Cap: $0.0B
ALMDP.PA
Medesis Pharma S.A.
$0.35
Mkt Cap: $0.0B
ALPHA.PA
Pharnext S.A.
$0.00
Mkt Cap: $0.0B
ALQGC.PA
Quantum Genomics S.A.
$0.07
Mkt Cap: $0.0B
APM.PA
Aptorum Group Limited
$3.21
Mkt Cap: $0.0B
MLAHC.PA
Health S.A.
$0.60
Mkt Cap: $0.0B
PHXM.PA
PHAXIAM Therapeutics S.A.
$0.10
Mkt Cap: $0.0B
Explore stocks similar to LYS.PA for comparison